ArticleEuropean journal of nuclear medicine and molecular imaging2019
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Metabolomics: A Tool to Envisage Biomarkers in Clinical Interpretation of Cancer.Current drug research reviews · 2024Review
- The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.Biomedicines · 2022Review
- Event-free survival afterEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Bilayer Forming Phospholipids as Targets for Cancer Therapy.International journal of molecular sciences · 2022Review
- [ACS omega · 2022Article
- The Metabolic Signature of AML Cells Treated With Homoharringtonine.Frontiers in oncology · 2022Article
- Article
- Deep learning-based quantification of PET/CT prostate gland uptake: association with overall survival.Clinical physiology and functional imaging · 2020Article
- Prospective comparison of whole-body MRI andEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe main drawback of
methodsThis retrospective study included 210 PCa patients treated with radical prostatectomy who underwent
resultsMedian follow-up after radical prostatectomy was 6.9 years (95% confidence interval, CI, 2.0-14.5 years).
conclusionDespite the relatively low positive detection rate for PSA < 1 ng/ml, positive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.